Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20414839 | 0.89 | GLP1R (0.61) | NOD1FOLH1GLP1R | |
| SCHEMBL20528860 | 0.88 | FOLH1 (0.49) | NOD1FOLH1 | |
| SCHEMBL20528861 | 0.88 | FOLH1 (0.49) | NOD1FOLH1 | |
| SCHEMBL30905812 | 0.88 | NOD1 (0.64) | NOD1FOLH1GLP1REPHX2 | |
| SCHEMBL24179874 | 0.88 | GLP1R (0.48) | NOD1FOLH1GLP1R | |
| SCHEMBL21170437 | 0.87 | NOD1 (0.53) | NOD1FOLH1GLP1REPHX2GNPAT | |
| SCHEMBL21172243 | 0.86 | NOD1 (0.58) | NOD1FOLH1GLP1REPHX2 | |
| SCHEMBL23365799 | 0.86 | NOD1 (0.58) | NOD1FOLH1GLP1REPHX2 | |
| SCHEMBL21126875 | 0.86 | NOD1 (0.52) | NOD1FOLH1GLP1REPHX2GNPAT | |
| SCHEMBL21172899 | 0.86 | NOD1 (0.55) | NOD1FOLH1GLP1REPHX2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11219690-B2 | Method for thioether conjugation of proteins | NOVO NORDISK HEALTHCARE AG (CH) | 2022-01-11 | — | — | US | disclosed |
| EP-3079722-B1 | METHOD FOR THIOETHER CONJUGATION OF PROTEINS | NOVO NORDISK HEALTHCARE AG (CH) | 2021-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219690-B2 | Method for thioether conjugation of proteins | TST, P4HB, PDIA6 | NOD1 2513/4885FOLH1 205/4885GLP1R 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.